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Abstract In heart failure, intracellular Ca
2? leak from
cardiac ryanodine receptors (RyR2s) leads to a loss of Ca
2?
from the sarcoplasmic reticulum (SR) potentially contri-
buting to decreased function. Experimental data suggest
that the 1,4-benzothiazepine K201 (JTV-519) may stabilise
RyR2s and thereby reduce detrimental intracellular Ca
2?
leak. Whether K201 exerts beneﬁcial effects in human
failing myocardium is unknown. Therefore, we have
studied the effects of K201 on muscle preparations from
failing human hearts. K201 (0.3 lM; extracellular [Ca
2?]e
1.25 mM) showed no effects on contractile function and
micromolar concentrations resulted in negative inotropic
effects (K201 1 lM; developed tension -9.8 ± 2.5%
compared to control group; P\0.05). Interestingly, K201
(0.3 lM) increased the post-rest potentiation (PRP) of
failing myocardium after 120 s, indicating an increased SR
Ca
2? load. At high [Ca
2?]e concentrations (5 mmol/L),
K201 increased PRP already at shorter rest intervals (30 s).
Strikingly, treatment with K201 (0.3 lM) prevented dia-
stolic dysfunction (diastolic tension at 5 mmol/L [Ca
2?]e
normalised to 1 mmol/L [Ca
2?]e: control 1.26 ± 0.06,
K201 1.01 ± 0.03, P\0.01). In addition at high [Ca
2?]e,
K201 (0.3 lM) treatment signiﬁcantly improved systolic
function [developed tension ?27 ± 8% (K201 vs. control);
P\0.05]. The beneﬁcial effects on diastolic and systolic
functions occurred throughout the physiological frequency
range of the human heart rate from 1 to 3 Hz. Upon ele-
vated intracellular Ca
2? concentration, systolic and dia-
stolic contractile functions of terminally failing human
myocardium are improved by K201. Electronic supplementary material The online version of this
article (doi:10.1007/s00395-009-0057-8) contains supplementary
material, which is available to authorized users.
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Introduction
Patients with chronic heart failure (HF) exhibit depressed
contractile function and ventricular arrhythmias, which
may result in sudden death. Abnormal intracellular Ca
2?
handling is a likely mechanism contributing to decreased
force development and has been associated with impaired
SR Ca
2? storage function [3, 4, 15]. Luminal SR Ca
2?
concentrations are determined by diastolic SR Ca
2? uptake
through ATPases (SERCA2s) as well as diastolic Ca
2?
leak via ryanodine receptors (RyR2s). Although the
dynamic leak-load relationship may limit SR Ca
2? loss
resulting from decreased SERCA2 function in HF [23],
chronically increased RyR2 open probability may impair
contractile performance [27] and may also lead to triggered
arrhythmias [24].
Recently, novel pharmacological and genetic therapeu-
tic strategies were developed which target abnormal
intracellular Ca
2? cycling in HF and arrhythmias [5, 13,
22]. Among these, the 1,4-benzothiazepine compound
K201 (also known as JTV-519 [9]) has shown beneﬁcial
effects in animals with HF [28, 31] or arrhythmias [26].
K201 has multiple sites of action in the heart. The most
interesting action of K201 is the ability to induce a con-
formational change in RYR reducing its open probability
[30]. Other actions of K201 are the inhibition of SERCA
[14] and several sarcolemmal ion-channels [10]. These
different actions were demonstrated to depend on the
concentration of K201 and concentrations up to
1 lM K201 are used to ensure RYR-mediated effects [12].
To investigate the efﬁcacy of K201 to improve human
cardiac muscle function, intact muscle preparations form
terminally failing human hearts were used, and the force
frequency response (FFR) and post-rest potentiation (PRP)
protocols were applied to study SR-dependent muscle
performance [18]. In particular, PRP has been shown to
correlate with SR Ca
2? content [19]. Our data identify
potentially beneﬁcial K201 effects on contractile function
in terminally failing human hearts.
Methods
Muscle preparation
Human ventricular muscle strips were dissected from
freshly explanted hearts of 14 end-stage heart failure
patients undergoing cardiac transplantation as a result of
ischemic or dilated cardiomyopathy (12 men and 2 women,
average age 42.2 ± 4.2 years). Unfortunately, the analysis
of non-failing myocardium was not possible due to the lack
of available tissue. Detailed patient characteristics are
provided in the online supplement. The investigation con-
forms to the principles outlined in the Declaration of
Helsinki. The study was approved by the institutional
ethics committee, and all patients provided written
informed consent for the use of cardiac tissue samples.
Hearts were transported in a Krebs–Henseleit buffer (KHB)
with 2,3-butanedione monoxime as cardioplegic solution
[8]. Intact trabeculae were carefully microdissected from
the left ventricle and ﬁxed between a force transducer
(Scientiﬁc Instruments) and a hook connected to a micro-
manipulator for length adjustment. Only trabeculae with a
diameter of 0.5 mm or less were used for experiments.
Mean dimensions (mm) were as follows: diameter 1
0.40 ± 0.01; diameter 2 0.36 ± 0.01; length 2.2 ± 0.1.
The distribution of the muscle diameter was not different
between the analysed groups. After wash-out of the car-
dioplegic solution, muscle preparations were superfused
with Krebs–Henseleit solution (containing in mmol/L: 137
NaCl, 5.4 KCl, 1.2 MgSO4, 1.2 NaH2PO4, 20 HEPES, 10
glucose, 0.25 CaCl2; pH adjusted to 7.4 with NaOH) and
electrically stimulated (baseline 1 Hz, amplitude 3–5 V;
stimulator Scientiﬁc Instruments type STIM2). Force
measurements were carried out at 37C and either at 1.25
or 5 mmol/L [Ca
2?]o. After 60 min of equilibration, the
muscles were stretched gradually to the length at which
maximum steady-state twitch force was reached (Lmax).
Experimental protocol
K201 was a gift from Aetas Pharma Ltd. (Japan). The drug
was dissolved in DMSO (99.7%, Sigma-Aldrich, Taufkir-
chen, Germany) to achieve a nominal stock concentration
of 1 mmol/L. To determine the effect of K201 on basal
contractile performance, K201 was added to the circulating
KHB solution in different concentrations (0.1, 0.3, 1, 3, 10,
30 lM) and compared to the control group treated with the
drug carrier (DMSO, same vol% dilution corresponding to
each K201 step). The developed tension (Tdev), diastolic
tension (Tdia), time to peak (TTP) and time to 50 and 90%
relaxation (RT50 and RT90) were recorded online using
LabView (National instruments).
In all further experiments (Fig. 1), K201 was added to
the solution at least 60 min before assessment of muscles
strip function. Force-frequency relationship and PRP were
analysed in K201 (0.3 or 1 lM) treated preparations. The
FFR was examined at a range of 0.25–3 Hz and normalised
to 0.25 Hz. Force recording of isometric tension was
obtained at steady-state conditions at each frequency step.
PRP was examined using rest intervals of 1–120 s (1, 2, 4,
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1238, 16, 30, 60, 120 s). The tension developed on the ﬁrst
twitch after rest was divided by the mean developed ten-
sion of the last ten beats before rest.
To provoke an increase in SR Ca
2? leak and diastolic
tension extracellular calcium ([Ca
2?]e) was elevated step-
wise from 1.25 to 5 mmol/L [1, 2.] Upon steady state, PRP
protocol was conducted as described above to ascertain
equal starting conditions in all groups. Then the muscles
were randomised to treatment with either K201 at 0.3 or
1 lM or DMSO and left contracting for 2 h. After 2 h the
PRP was repeated again.
To examine the inﬂuence of calcium on diastolic tension
muscles were treated with 0.3 lM K201 or DMSO at the
start of the experiment and stretched to Lmax at 1.0 mmol/L
[Ca
2?]e. Upon steady state the [Ca
2?]e was increased
stepwise (1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0) to
5 mmol/L. Contractile parameters were analysed after
every step. Finally, FFR was measured in these muscles
strips with 5 mmol/L [Ca
2?]e.
Mean developed tension of failing human myocardial
muscle strips at 1 Hz was 12.2 ± 2.1 mN/mm
2.
Calculation and statistics
Tension measurements were normalised to the cross-sec-
tional area for each preparation, calculated assuming an
elliptical cross section using the formula cross-sectional
area = D1/2 9 D2/2 9 p, with D1 and D2 representing
width and thickness, and expressed as tension. Determined
parameters were expressed as the ratio of the respective
baseline parameter. Contractile parameters at different
K201 concentrations were analysed using using two-way
ANOVA or paired Students t test where appropriate, with
values of P\0.05 considered statistically signiﬁcant.
Results
Concentration-dependent response to K201
Compared to control (n = 6), developed tension (Tdev)
remained unchanged until 0.3 lM K201 and declined at a
concentration of 1 lM( 1 lM: 9.8 ± 2.5% of control,
Protocol 4: stepwise calcium elevation and FFR at 5mM [Ca2+]e
Protocol 1: dose response 
0 0.5 1 1.5 2 Time [h]
Start Stretch K201 
Protocol 2: FFR, PRP at 1.25mM [Ca2+]e
0 0.5 1 1.5 2 2.5 3 3.5 4
K201 Stretch PRP FFR
Time [h]
Protocol 3: PRP at 5mM [Ca2+]e
0 0.5 1 1.5 2 2.5 3 3.5 4
Calcium Stretch PRP1 PRP2
Time [h]
K201
0 0.5 1 1.5 2 2.5 3 3.5 4
K201 Stretch Calcium FFR
Time [h]
Next concentration after steady state or 15min.
Fig. 1 Schematic diagram of
the experimental protocols.
K201 Addition of K201, Stretch
stretch of the muscles strip to
Lmax, FFR measurement of the
force frequency relationship,
PRP measurement of the post
rest potentiation, Calcium
increase of the [Ca
2?]e from
1.25 mmol/l stepwise to
5.0 mmol/l
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123P\0.05, n = 6, Fig. 2). Higher doses of K201 lead to a
further reduction of Tdev.A t3 0lM the developed tension
was reduced to only 23 ± 5% (P\0.001) of control. The
half-maximalinhibitoryconcentration(IC50)ofK201onthe
developed tension was 8.7 lM (Supplementary ﬁgure 1).
Effects of K201 on contractile performance at low
[Ca
2?]e in failing human hearts
Isolated ventricular muscle preparations from terminally
failing human hearts did not show an acutely improved
contractile function following K201 at 0.3 lM and clearly
K201 may be acutely negatively inotropic at high concen-
trations (Fig. 2; Supplementary ﬁgure 1). However, K201
has a profound effect on post rest potentiation even at
concentrations of 0.3 lM, where contractility is largely
preserved (Fig. 3a). In human failing cardiac muscle strips
we typically observe a robust post rest potentiation
(Fig. 3b). Up to 16 s the increase in post rest potentiation
was similar between K201 or control treated muscle strips
(increase from 0 to 16 s: control: 93 ± 17%; 0.3 lM K201:
87 ± 12%; 1 lM K201: 94 ± 11%, each P\0.01,
Fig. 3b). At longer rest intervals, a further increase in post
rest potentiation was visible in the K201 treated muscles
strips (increase from 16 to 120 s: 0.3 lM K201: 59 ± 27%;
1 lM K201: 62 ± 34%, each P\0.05), but not in the
control group (increase from 16 to 120 s: 7 ± 14%,
P = 0.61, Fig. 3c).
Additionally, we observed a frequency-dependent sig-
niﬁcant increase in diastolic tension and a blunted increase
in systolic tension in failing human myocardium. However,
both diastolic and systolic FFR were not signiﬁcantly
altered by either K201 treatement (0.3 or 1 lM) compared
to control (Supplementary ﬁgure 2). These results are in
agreement with earlier data from failing human myocar-
dium demonstrating that the phenotype of increased dia-
stolic tension in combination with a blunted FFR is
associated with decreased SERCA2 and increased NCX
function, further contributing to depletion of intracellular
Ca
2? stores through competitive mechanisms and
explaining the relatively long PRP needed to observe
beneﬁcial efﬁcacy of K201 earlier.
Inﬂuence of K201 treatment on PRP behaviour
at elevated [Ca
2?]e in human failing hearts
Since our initial data indicated that K201 effects on PRP
behaviour required relatively long rest intervals under
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Fig. 2 Example of recorded
contraction before and
following addition of vehicle
control (DMSO, a) or K201 (b)
in concentrations from 100 nM
to 30 lM at 1 Hz. c Effect on
developed tension in human
failing muscles strips [K201
dotted line vs. control (DMSO)
solid line, each n = 6]
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123relatively Ca
2? deprived conditions, we investigated PRP
before and after prolonged (2 h) treatment with 0.3 or
1 lM K201 (Fig. 4a, b). Before treatment PRP was not
different between the experimental groups (Fig. 4c).
However, PRP was signiﬁcantly increased by 38 and 35%
using 0.3 or 1 lM K201, respectively (normalised increase
after a rest interval of 120 s: 1.68 ± 0.12 in the control
group and 2.32 ± 0.24 and 2.28 ± 0.20 in the K201 group
with a concentration of 0.3 and 1 lM, respectively
P\0.05, Fig. 4d).
Effect of K201 on contractile performance during
elevation of [Ca
2?]e in human failing hearts
Since our initial data indicated that K201 effects on PRP
behaviour required relatively long rest intervals under rela-
tively Ca
2? deprived conditions, we investigated failing
ventricular preparations at supra-physiological [Ca
2?]e
concentrations. Above normal [Ca
2?]e can be expected to
lead to a relative increase in SR intraluminal Ca
2? con-
centrations [20]; however, the pre-existing competition
between SERCA2 and NCX can be expected to partially
extrude the additional and potentially inotropic Ca
2? to the
extracellular side. Therefore, K201 by inhibiting SR Ca
2?
leak may improve SR Ca
2? load independently from pre-
existing SERCA2 and NCX mechanisms. As expected,
increased [Ca
2?]e (5 mmol/L) resulted in a signiﬁcant
increase in diastolic tension (Fig. 5a) of ?25.7 ± 5.9%
(relative to baseline conditions at 1 mmol/L; P\0.05,
each n = 7; Fig. 4c). However, K201 treatment (0.3 lM)
abolished the increase in diastolic tension (n = 7,
P\0.001, Fig. 5b, c). Additionally, following the same
K201 treatment developed tension (Tdev) was signiﬁcantly
increased by ?27 ± 8% (P\0.05; Fig. 5c) at 5 mmol/L
[Ca
2?]e. In agreement with earlier reports [16], myocardial
relaxation was signiﬁcantly prolonged at higher Ca
2?
concentrations in control preparations (RT90 1.0 vs.
5.0 mmol/L [Ca
2?]e: ?19 ± 7%, P\0.05). However,
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123K201 treatment prevented the increase in relaxation time
(RT90 1.0 vs. 5.0 mmol/L [Ca
2?]e: ?14 ± 10%, not sig-
niﬁcant). Thus, our data indicate that K201 exerts beneﬁ-
cial effects including myocardial contraction and relaxation
in failing human myocardium.
Inﬂuence of K201 on the FFR at elevated [Ca
2?]e
in human failing hearts
Increasing the stimulation frequency in muscles strips with
elevated [Ca
2?]e leads to a frequency-dependent decline in
developed tension and an increase in diastolic tension.
Taking into account that the contractile performance at
1 Hz was already different in the K201-treated group
compared to control, the frequency-dependent changes in
developed and diastolic tension were normalised to the
tension at 1 Hz and 1.0 mmol/L [Ca
2?]e (Fig. 6a, c). The
contractile improvement by K201 was preserved also at
higher frequencies (Fig. 6b, d). The developed tension was
higher in the K201-treated muscles strips at the stimulation
frequencies from 1 to 3 Hz (K201 vs. control: 1 Hz:
2.99 ± 0.25 vs. 2.35 ± 0.11; 2 Hz: 1.50 ± 0.23 vs.
0.89 ± 0.14; 3 Hz: 0.65 ± 0.09 vs. 0.39 ± 0.06; each
n = 7 and P\0.05, Fig. 6b). Also the diastolic tension
was lower throughout the whole rage of the FFR (K201 vs.
control: 1 Hz: 1.01 ± 0.03 vs. 1.25 ± 0.06; 2 Hz:
1.69 ± 0.35 vs. 3.07 ± 0.69; 3 Hz: 2.13 ± 0.47 vs.
3.75 ± 0.75; each n = 7 and P\0.05, Fig. 6d).
Discussion
Our data suggest that the 1,4-benzothiazepine K201
improves both diastolic and systolic contractile function of
failing human myocardium. The following observations
support these conclusions: (1) PRP ([Ca
2?]e 1.25 mM) was
improved by K201 at longer post-rest intervals; (2) K201
([Ca
2?]e 5 mM) improved PRP at shorter post-rest inter-
vals; (3) K201 prevented diastolic dysfunction and
improved systolic function under Ca
2? overload condi-
tions; (4) the beneﬁcial effects on systolic and diastolic
function were maintained throughout the physiological
frequency range of the human heart.
Importantly, systolic improvement is conﬁned to low
concentrations of K201 as higher concentrations are clearly
negatively inotropic.
Apart from the potentially therapeutic effects of K201 on
RyR2 dysfunction and intracellular Ca
2? leak [9, 11, 12],
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123K201 has documented off-target effects at high micromolar
concentrations. Therefore, the negative inotropic effect on
developed tension in failing human myocardial preparations
may be attributed to inhibitory actions of micromolar K201
concentrations on L-type Ca
2? currents and SERCA [10,
14]. However, at nanomolar concentrations of K201
(0.3 lM), no adverse effects on the contractile performance
of failing human myocardium were observed. Additionally,
at low physiological [Ca
2?]e contractile function was not
affected by K201 treatment in failing muscle preparation.
This ﬁnding is in agreement with studies showing that SR
Ca
2? leak depends on sufﬁcient SR Ca
2? load [29] and that
extracellular Ca
2?-depletion leads to reduced SR Ca
2? load
and reduced SR Ca
2? leak [23]. Thus, our data under low
[Ca
2?]e conditions agree with the hypothesis that K201
targets SR Ca
2? leak but, importantly, does not block
physiological SR Ca
2? release and therefore exerts no
beneﬁcial or adverse effects. Additionally, K201 showed
signiﬁcant beneﬁcial effects on PRP at longer post-rest
intervals which have been associated with increased SR
Ca
2? load [20]. Again, these data support that K201 effects
depend on the existence of signiﬁcant SR Ca
2? leak in
human failing muscle strips due to longer SR Ca
2? load
periods.
Kimura et al. [10] showed that the half-maximal inhi-
bitory concentration (IC50) of K201 on plasma membrane
ion currents is 5 lM. Loughrey et al. [14] showed that
K201 in a concentration of 3 lM signiﬁcantly reduced
SERCA activity. However, we have not observed any
adverse changes on FFR behaviour throughout the entire
physiological frequency range of the human heart with
control
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to a magnitude order lower K201 concentrations.
Indeed, experiments with human cardiac muscle prepa-
rations have been established as a solid model of cardiac
excitation–contraction-coupling. For example, it has been
shown that the FFR in isolated muscle preparations
resembles the FFR in patients with HF [6], and that
intracellular Ca
2? cycling is depressed in muscle prepa-
rations following post-rest activation [20]. Accordingly,
we have used increased [Ca
2?]e as a model of increased
intracellular Ca
2? load in accordance with previously
established protocols [1, 2] to characterise potential bene-
ﬁcial effects of K201 under conditions of increased SR
Ca
2? leak as shown earlier [14]. As we did not measure
Ca
2? directly, our study relies on previous observations
showing that SR Ca
2? leak is a function of SR Ca
2? load
[29] and that SR Ca
2? concentration in intact cardiac
myocytes depends directly on intracellular Ca
2? concen-
tration [23]. Importantly, an increase in intracellular Ca
2?
concentration was achieved by increasing [Ca
2?]e as
reported earlier in non-human material [1] and was
reported to be associated with multiple spontaneous SR
Ca
2? release events [14].
Indeed, following K201 treatment, failing human mus-
cle strip preparations showed improved PRP behaviour at
shorter post-rest intervals under high [Ca
2?]e conditions.
These results are in line with previously published animal
data [11, 27] and demonstrate beneﬁcial effects of nano-
molar concentrations of K201 (0.3 lM). Our results con-
ﬁrm earlier animal studies by Kohno et al. [11] who have
found efﬁcacy of K201 against intracellular Ca
2? leak at
the same concentration.
A limitation of our study is the lack of direct Ca
2?
measurements. Although this was achieved technically in
the past, in our hands it is clearly not possible to obtain
these measurements at physiological temperature and
stimulus rates (whereas the data presented here was mea-
sured at 37C under near physiological conditions).
A signiﬁcant ﬁnding is that K201 improved both dia-
stolic and developed tension throughout the physiological
frequency range of the human heart. Indeed, altered FFR is
an important pathophysiological mechanism of reduced
cardiac performance and altered stress adaptation in human
HF [18, 21]. The combined beneﬁcial effects of K201 on
diastolic function and the FFR behaviour in failing human
myocardium indicate potentially beneﬁcial effects of 1,4-
benzothiazepines which are distinct from existing phar-
macological strategies.
Previously the mechanism of K201 on RYR2 stabilisa-
tion could be further deciphered: Yamamoto et al. [32]
found that the K201-binding site on RYR2 is the domain
(2114–2149). Interdomain interaction of RyR2 becomes
loose in failing hearts, resulting in SR Ca leak [17, 25].
Addition of K201 to the destabilised RyR2 restores a stable
conﬁguration, i.e. inter-domain interaction, as in RyR2
from non-failing myocardium [32]. Rebinding of
FKBP12.6 to RyR2 in failing SR seems not to be required
to induce the K201 effects on RYR2 [7, 17], but K201
facilitates rebinding of FKBP12.6 in some cases [26, 30],
suggesting that K201 may act primarily by modifying
domain–domain interaction, but less via FKBP12.6.
We observed a negative inotropic effects at higher
concentrations of K201 suggesting a detrimental effect on
cardiac performance in failing human hearts. Although this
ﬁnding does not necessarily imply an unfavourable effect
in heart failure (i.e. b-blocker therapy paradoxically
improves cardiac function in heart failure), we suggest
K201 should be used at concentrations lower than 1 lM
when initially examined in humans. Our ﬁndings suggest
that at such low concentrations there is already a profound
effect on calcium cycling in human myocytes without
negative inotropy. This gives support to the concept that
the antiarrhythmic effects evident in multiple animal
models at these lower K201 concentrations will be also
present in humans.
In summary, this study demonstrates that K201
improved some aspects of the contractile performance in
the human failing myocardium at lower concentrations
(0.3 lM) consistent with reduced SR calcium leak.
Therefore K201 may, in addition to previously reported
anti-arrhythmic effects, improve contractile performance in
the failing human heart.
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